Clinical Research Directory
Browse clinical research sites, groups, and studies.
An Expanded Access Program for SYN023 in Rabies Treatment
Sponsor: Synermore Biologics (Suzhou) Co., Ltd.
Summary
This sponsor-initiated Expanded Access Program provides compassionate-use SYN023, a dual monoclonal antibody cocktail (zamerovimab + mazorelvimab) targeting rabies virus glycoprotein, for US patients with confirmed or suspected life-threatening rabies lacking adequate alternative therapies.
Official title: Sponsor-Initiated Expanded Access Program (SYN023-EAP-001) for SYN023 (Zamerovimab + Mazorelvimab): Compassionate Use of SYN023 in Patients With Confirmed or Suspected Life-Threatening Rabies Infection
Key Details
Gender
All
Age Range
Any - Any
Study Type
EXPANDED_ACCESS
Enrollment
Not specified
Start Date
Not specified
Completion Date
Not specified
Last Updated
2026-07-16
Healthy Volunteers
Not specified
Conditions
Interventions
Zamerovimab and Mazorelvimab Injection
SYN023 may be administered with rabies treatments according to the local standard of care; local standard of care may include the Milwaukee Protocol if the treating clinician and patient so choose.